| Patent Number |
Title Of Patent |
Date Issued |
| 6479632 |
Tumor necrosis factor inhibitory protein and its purification |
November 12, 2002 |
| Tumor Necrosis Factor (TNF) Inhibitory Protein is isolated and substantially purified. It has the ability to inhibit: (a) the binding of TNF to its receptors, and (b) the cytotoxic effect of TNF.TNF Inhibitory Protein and salts, functional derivatives and active fractions thereof can be |
| 5981701 |
Tumor necrosis factor inhibitory protein and its purification |
November 9, 1999 |
| Tumor Necrosis Factor (TNF) Inhibitory Protein is isolated and substantially purified. It has the ability to inhibit: (a) the binding of TNF to its receptors, and (b) the cytotoxic effect of TNF. TNF Inhibitory Protein and salts, functional derivatives and active fractions thereof can |
| 5811261 |
Expression of the recombinant tumor necrosis factor binding protein I (TBP-I) |
September 22, 1998 |
| Tumor Necrosis Factor Binding Protein I (TBP-I), precursors and analogs thereof, are produced by transfecting eukaryotic cells with an expression vector comprising al DNA molecule encoding the whole human type I TNF receptor or a soluble domain thereof, and culturing the transfected cell |
| 5695953 |
DNA that encodes a tumor necrosis factor inhibitory protein and a recombinant method of producti |
December 9, 1997 |
| Tumor Necrosis Factor (TNF) Inhibitory Protein is isolated and substantially purified and the DNA that encodes the TNF inhibitory protein, vectors, host cells, and a recombinant method for producing the encoded protein are also set forth. It has the ability to inhibit: (a) the bindin |
| 5512544 |
Pharmaceutical compositions comprising an anticytokine |
April 30, 1996 |
| Tumor Necrosis Factor Binding Proteins (TBPs) are useful in the treatment of autoimmune diseases and graft-versus-host reactions. |
| 5462731 |
Use of IL-6 for the treatment of chronic lymphocyte leukemia (CLL) and B-cell lymphomas |
October 31, 1995 |
| The use of interleukin-6 and/or salts, functional derivatives, muteins or active fractions thereof, in the treatment of chronic lymphocytic leukemia and B-cell lymphomas, as well as such use together with the soluble interleukin-6 receptor, to pharmaceutical compositions and to a method |
| 5359037 |
Antibodies to TNF binding protein I |
October 25, 1994 |
| Antibodies to TNF Binding Protein I (TBP-I) are provided that can be used in diagnostic assays and as pharmaceutical agents for either inhibiting or mimicking the effects of TNF on cells. |
